US$ 23.44
long term side effects of glp-1 receptor agonists Mapping the effectiveness and risks How does Ozempic work? The
Description
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial

This 72-week study compared the efficacy and safety of subcutaneous semaglutide 7.2 mg against semaglutide 2.4 mg and a placebo, all administered weekly, in 1,407 adults with obesity who also participated in lifestyle interventions

[DOI] [PMC free article] [PubMed] [Google Scholar] 115.9

The shorter half life requires daily administration but allows for relatively quick dose adjustments when needed

BioLingus GmbH D&D Pharmatech Inc
